昆药集团：12月9日召开董事会会议

Group 1 - The core point of the article is that Kunming Pharmaceutical Group announced a board meeting to discuss the addition of non-independent directors and provided a breakdown of its revenue composition for 2024 [1] - The company's revenue composition for 2024 is as follows: oral formulations account for 43.95%, pharmaceutical wholesale and retail account for 43.51%, injections account for 6.42%, other businesses account for 5.26%, and other categories account for 0.87% [1] - As of the report, Kunming Pharmaceutical Group has a market capitalization of 9.8 billion yuan [1] Group 2 - The article also highlights a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, which raises concerns about prescription drug misuse [1] - There are vulnerabilities in online platforms that allow the purchase of medications without proper medical records, indicating a need for regulatory scrutiny [1] - The classification of pregabalin and its potential regulation is still under scientific consideration, reflecting ongoing debates in the industry [1]